Nuclear Hype Fades as Short Sellers Bank $2.1bn
According to S3 Partners, short sellers made an estimated $2.1bn betting against NuScale Power, Nano Nuclear and Oklo. The firms’ combined market value fell by $30.3bn since their Oct peak, as investor enthusiasm for SMRs cooled amid limited near-term revenue and long development timelines. The article also cites X-energy’s $5.8bn decline and S&P data on shares on loan.
How this was made
The 30-second read
Why it matters
It argues that investor concerns about limited near-term revenue and long development timelines have driven short sellers to increase bets, with quantified share-on-loan proxies and market-value drawdowns.
Market read
Provides a quantified snapshot of bearish positioning (shorting estimates and shares on loan) across several US-listed SMR/microreactor developers amid a sentiment reversal.
What to watch
The article emphasizes bearish sentiment but provides limited detail on any incremental progress (licensing, engineering, financing) that could counter the valuation narrative.
Background
The article frames a reversal from last year’s SMR enthusiasm, citing regulatory and funding optimism that has since faded.
Ticker impact
Article cites short sellers betting against NuScale Power and notes about 18% of its shares are out on loan, signaling bearish positioning.
Near-term pressure risk if borrow/shorting remains elevated, though it is not a new fundamental catalyst.
The piece provides quantified shorting/balance-sheet context but no new regulatory, financing, or operational milestone for SMR.
Article says short sellers have increased bets against Oklo and that about 18% of its outstanding shares are out on loan.
Potential volatility to the downside if the market continues to price long-dated commercialization risk.
The article’s core new datapoint is the scale of shorting and the sentiment shift, not a fresh Oklo-specific event.
Market effects
Reinforces a sector-wide de-risking narrative for SMR developers, with valuation compression tied to long commercialization timelines.
Primarily impacts US-listed SMR names; could spill over to global nuclear supply-chain sentiment.
Highlights investor skepticism toward SMR commercialization schedules, despite continued long-term demand narratives.
Counterpoint
Shorting and share-on-loan metrics may reflect hedging or liquidity dynamics rather than a definitive fundamental deterioration for each company.
Key entities
- companyNuScale Power
US-listed SMR developer referenced as a target of increased short selling, with shares out on loan cited.
- companyOklo
US-listed SMR developer backed by Sam Altman, referenced with share-on-loan and shorting activity.
- companyNano Nuclear
US-listed microreactor developer referenced with high shares out on loan and no revenue history.
- companyX-energy
US-listed helium-cooled reactor developer referenced with post-IPO market-value decline and short-profit estimates.
- companyHoltec International
Expected to list its SMR division, cited as a near-term catalyst for investor appetite.
